Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2096678 Target Snapshot

Endothelin receptor, ET-A/ET-B · PROTEIN FAMILY · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
261Compounds
29Assays
0Approved Drugs
9.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Endothelin receptor, ET-A/ET-B shows approved-linked disease relevance led by hypertension. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P24530. Start with hypertension, then reuse UniProt P24530 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with hypertension, then reuse UniProt P24530 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 5 linked drugs
Open source guide
Disease program
hypertension

Endothelin receptor, ET-A/ET-B shows approved-linked disease relevance led by hypertension. 5 more disease programs remain visible in the same review block. 5 linked drugs remain visible in the same block.

Start review with hypertension because it currently carries approved-linked support. Linked drugs include AMBRISENTAN, APROCITENTAN, BOSENTAN, MACITENTAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 5 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Endothelin receptor, ET-A/ET-B as ChEMBL target CHEMBL2096678, mapped to UniProt P24530. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Endothelin receptor, ET-A/ET-B
PROTEIN FAMILY · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2096678
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P24530
Endothelin receptor type B
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Endothelin receptor, ET-A/ET-B is the right protein anchor across sources, using UniProt P24530 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why hypertension is currently framed as approved-linked support. It currently carries 5 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameEndothelin receptor, ET-A/ET-B
Target TypePROTEIN FAMILY
OrganismHomo sapiens
UniProtP24530
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelEndothelin receptor type B
UniProt AccessionP24530
Component TypeProtein
Sequence Length442 aa

Endothelin receptor type B

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Endothelin receptor, ET-A/ET-B, mapped to UniProt P24530. ChEMBL maps the protein component as Endothelin receptor type B. Sequence length is 442 aa.

Mapped IDP24530
Review nameEndothelin receptor, ET-A/ET-B
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Endothelin receptor, ET-A/ET-B shows approved-linked disease relevance led by hypertension. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
hypertension
5 linked drugs · 5 direct · 5 efficacy
Linked drugAMBRISENTAN
Linked drugAPROCITENTAN
Linked drugBOSENTAN
Linked drugMACITENTAN
Approved-linked Approved
pulmonary hypertension
5 linked drugs · 5 direct · 5 efficacy
Linked drugAMBRISENTAN
Linked drugBOSENTAN
Linked drugMACITENTAN
Linked drugSITAXENTAN
Approved-linked Approved
pulmonary arterial hypertension
4 linked drugs · 4 direct · 4 efficacy
Linked drugAMBRISENTAN
Linked drugBOSENTAN
Linked drugMACITENTAN
Linked drugSITAXENTAN
Approved-linked Approved
idiopathic and/or familial pulmonary arterial hypertension
3 linked drugs · 3 direct · 3 efficacy
Linked drugAMBRISENTAN
Linked drugBOSENTAN
Linked drugMACITENTAN
Approved-linked Approved
pulmonary arterial hypertension
2 linked drugs · 2 direct · 2 efficacy
Linked drugAMBRISENTAN
Linked drugBOSENTAN
Approved-linked Approved
systemic scleroderma
2 linked drugs · 2 direct · 2 efficacy
Linked drugBOSENTAN
Linked drugMACITENTAN
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with hypertension because it currently carries approved-linked support. Linked drugs include AMBRISENTAN, APROCITENTAN, BOSENTAN, MACITENTAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasehypertension
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC501.0
KI2.0
KD6.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2373292 8.4 Kd 3.981 Preclinical
CHEMBL287169 7.5 Kd 31.62 Preclinical
CHEMBL27732 7.3 Kd 50.12 Preclinical
CHEMBL285368 7.0 Kd 100.0 Preclinical
CHEMBL28920 6.9 Kd 125.89 Preclinical
CHEMBL28563 6.3 Kd 501.19 Preclinical
Distribution

pChEMBL Value Distribution

0
5.0
0
5.5
1
6.0
1
6.5
2
7.0
1
7.5
1
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

29
Total Assays
7
Tested Compounds
2
Assay Types
Binding — 18 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
protein format 18 0 —
Functional — 11 assays, 7 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 5 0 —
assay format 3 1 8.4
tissue-based format 3 6 7.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine